SCHEMBL3335835

SCHEMBL3335835

CCOc1nc(N)nc2ccc(-c3ccc(C(=O)NCCN(C)C)cc3)cc12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.53
BRAF P15056 2/20 0.49
PRKD3 O94806 1/20 0.48
PRKD1 Q15139 1/20 0.48
PRKD2 Q9BZL6 1/20 0.48
MAP4K4 O95819 2/20 0.44
MELK Q14680 1/20 0.44
HPGD P15428 1/20 0.43
HDAC4 P56524 1/20 0.42
HDAC1 Q13547 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
ALOX5 P09917 1/20 0.42
TLR7 Q9NYK1 1/20 0.42
GPR84 Q9NQS5 1/20 0.42
TP53 P04637 2/20 0.42
LMNA P02545 1/20 0.42
KDM4E B2RXH2 1/20 0.41
TET3 O43151 1/20 0.41
TET2 Q6N021 1/20 0.41
TET1 Q8NFU7 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3331769 0.88 KDM4E (0.47) ALDH1A1BRAFHPGDTLR7KDM4E
SCHEMBL3341434 0.88 MELK (0.46) ALDH1A1BRAFPRKD3PRKD1PRKD2
SCHEMBL3333686 0.87 BRAF (0.47) ALDH1A1BRAFPRKD3PRKD1PRKD2
SCHEMBL3338030 0.84 PLK1 (0.46) TP53MCHR1
SCHEMBL3337998 0.84 HPGD (0.51) ALDH1A1HPGDHDAC4TLR7KDM4E
SCHEMBL823719 0.83 MAP4K4 (0.52) ALDH1A1BRAFPRKD3PRKD1PRKD2
SCHEMBL3336819 0.83 DHFR (0.39) ALDH1A1BRAFMCHR1
SCHEMBL3337189 0.83 MAPK1 (0.52) ALDH1A1MAP4K4HPGDHDAC1TP53
SCHEMBL3340058 0.83 IP6K1 (0.45) MAP4K4
SCHEMBL3331389 0.82 CYP3A4 (0.50) ALDH1A1HPGDLMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8673929-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections GILEAD SCIENCES, INC. (US) 2014-03-18 US claimed
US-20100143299-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2010-06-10 US claimed
WO-2008009077-A2 4,6-DL- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2008-01-24 WO claimed
WO-2008009077-A2 4,6-DL- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2008-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100143299-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS OPRD1, IFNAR1, NR4A1 ALDH1A1 2902/4885BRAF 2516/4885PRKD3 2107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.